Home > Insider Trading > Filing (0001104659-25-033821)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1649904	Rhythm Pharmaceuticals Inc.	RYTM	Pharmaceutical Preparations (2834)	462159271

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1873517	J. Pamela Cramer	C/O Rhythm Pharmaceuticals, Inc. 222 Berkeley Street, 12Th Floor Boston MA 02116	Chief Human Resources Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2025-04-08	14,060	$6.80	33,269	No	4	M	Direct
Common Stock	Acquisiton	2025-04-08	6,700	$27.35	39,969	No	4	M	Direct
Common Stock	Disposition	2025-04-08	6,430	$58.36	33,539	No	4	S	Direct
Common Stock	Disposition	2025-04-08	600	$59.00	32,939	No	4	S	Direct
Common Stock	Disposition	2025-04-08	6,700	$60.00	26,239	No	4	S	Direct
Common Stock	Disposition	2025-04-08	7,030	$62.00	19,209	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Options (Right to Buy)	Acquisiton	2025-04-08	14,060	$0.00	14,060	$6.80
Common Stock	Stock Options (Right to Buy)	Acquisiton	2025-04-08	6,700	$0.00	6,700	$27.35

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
42,190		2032-02-08	No	4	M	Direct
20,100		2033-01-31	No	4	M	Direct

Footnotes

The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 16, 2024.
The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $58.00 to $58.735 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
The stock options were granted on February 1, 2023. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.